|
イマイ カズオ
IMAI Kazuo
今井 一男 所属 埼玉医科大学 医学部 臨床検査医学（中央検査部） 職種 専任講師 |
|
| 論文種別 | 学術雑誌(原著) |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | Clinical evaluation of the antibody response in patients with COVID-19 using automated high-throughput immunoassays. |
| 掲載誌名 | 正式名：Diagnostic microbiology and infectious disease |
| 巻・号・頁 | 100(3),115370-115370頁 |
| 著者・共著者 | Katsumi Kubota,Yutaro Kitagawa,Masaru Matsuoka,Kazuo Imai,Yuta Orihara,Rieko Kawamura,Jun Sakai,Noriomi Ishibashi,Norihito Tarumoto,Shinichi Takeuchi,Shigefumi Maesaki,Takuya Maeda |
| 発行年月 | 2021/07 |
| 概要 | Several automated high-throughput immunoassays for detecting anti-SARS-CoV-2 antibodies by a semi-quantitative approach have been commercialized. In this study, we describe the timeline of the antibody response in patients with RT-PCR-confirmed COVID-19. A total of 292 sequential serum samples from 33 Japanese patients were retrospectively analyzed using four test kits for SARS-CoV-2: the Abbott SARS-CoV-2 IgG assay (Abbott), Elecsys® Anti-SARS-CoV-2 assay (Roche Diagnostic), and VITROS® Anti-SARS-CoV-2 Total and IgG assays (Ortho Clinical Diagnostics). All automated immunoassays could equivalently identify positive sera collected within 2 weeks after symptom onset (99.3%-100%). In addition, the S protein-based automated immunoassay, the VITROS® Anti-SARS-CoV-2 Total assay, may play a complementary role in evaluating passive antibody therapies or vaccines against SARS-CoV-2, although further research is required. |
| DOI | 10.1016/j.diagmicrobio.2021.115370 |
| PMID | 33744623 |